|Bid||2.05 x 1000|
|Ask||2.20 x 2100|
|Day's Range||2.00 - 2.14|
|52 Week Range||1.30 - 5.35|
|PE Ratio (TTM)||-3.36|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Research Desk Line-up: Merus Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Titan Pharmaceuticals, ...
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that the first patient has been treated in a Phase 1/2 trial of the company's ropinirole implant intended for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Ropinirole is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of Parkinson's disease symptoms and restless leg syndrome. It is commonly used in conjunction with L-dopa to help control serious motor complications and dyskinesias that frequently occur in patients after several years of L-dopa treatment.
LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ), following which we have ...
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Opiant Pharmaceuticals, Inc. (OPNT) today announced a collaboration to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The companies will conduct a feasibility assessment of a subcutaneous implant using Titan's proprietary ProNeura™ sustained release technology to administer an opioid antagonist. A product that delivers non-fluctuating, therapeutic levels of an opioid antagonist, continuously for up to 6 months, may be ideally suited for the prevention of opioid relapse and overdose.
SANTA MONICA, Calif., Oct. 02, 2017-- Opiant Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. today announced a collaboration to explore development of a novel approach to the prevention of opioid ...